Please provide your email address to receive an email when new articles are posted on . More patients in the bezlotoxumab group experienced recurrence vs. the placebo group (13% vs. 3%). Steroid use ...
In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...
A study, published in Infection Control & Hospital Epidemiology, examined the factors associated with first Clostridium difficile infection that predict the use of fecal microbiota transplantation for ...
Fecal microbiota transplantation (FMT), shown to be effective in the treatment of recurrent Clostridioides difficile infection (CDI), also shows significant benefit in the treatment of primary CDI, ...
C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive system. It is one of the most common causes of diarrhea linked to ...
Bethesda, MD (Feb. 21, 2024) — In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results